Short Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Decreases By 21.9%
Short Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Decreases By 21.9%
ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Rating) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 11,800 shares, a decline of 21.9% from the May 31st total of 15,100 shares. Based on an average daily trading volume, of 21,900 shares, the days-to-cover ratio is currently 0.5 days.
ProShares UltraShort納斯達克生物科技公司(納斯達克:BIS-GET評級)在6月份空頭股數的銷售額大幅下降。截至6月15日,空頭股數共有11,800股,較5月31日的15,100股減少21.9%。以日均成交量21,900股計算,目前天數與回補比率為0.5天。
Shares of BIS opened at $24.68 on Wednesday. The stock's fifty day moving average price is $29.23 and its two-hundred day moving average price is $26.20. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $15.86 and a 1 year high of $35.64.
週三,國際清算銀行的股價開盤報24.68美元。該股的50日移動均線價格為29.23美元,200日移動均線價格為26.20美元。ProShares UltraShort納斯達克生物科技的一年低點為15.86美元,一年高位為35.64美元。
Several institutional investors and hedge funds have recently modified their holdings of the business. IMC Chicago LLC bought a new stake in shares of ProShares UltraShort Nasdaq Biotechnology during the 1st quarter valued at $450,000. OLD Mission Capital LLC bought a new stake in shares of ProShares UltraShort Nasdaq Biotechnology during the 4th quarter valued at $266,000. Finally, UBS Group AG raised its stake in shares of ProShares UltraShort Nasdaq Biotechnology by 54.7% during the 1st quarter. UBS Group AG now owns 1,371 shares of the company's stock valued at $33,000 after purchasing an additional 485 shares during the period.
幾家機構投資者和對衝基金最近調整了對該公司的持股。IMC芝加哥有限責任公司在第一季度購買了ProShares UltraShort納斯達克生物科技公司的新股,價值45萬美元。舊使命資本有限責任公司在第四季度購買了ProShares UltraShort納斯達克生物科技公司的新股份,價值266,000美元。最後,瑞銀集團在第一季度增持了ProShares UltraShort納斯達克生物科技公司的股份54.7%。瑞銀集團(UBS Group AG)在此期間又購買了485股,目前持有1,371股該公司股票,價值33,000美元。
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
ProShares超納斯達克生物科技(基金)只尋求一天的投資結果,不尋求較長時期的投資結果。基金尋求扣除費用和費用前的每日投資結果,相當於該指數每日業績的兩倍(200%)。超過一個交易日的基金回報將是這段時間內每一天的回報的複合結果,這很可能與同期納斯達克生物技術指數(該指數)的回報兩倍(200%)不同。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on ProShares UltraShort Nasdaq Biotechnology (BIS)
- Get Defensive With These Three Upgrades
- Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.
- 3 Home Improvement Stocks That Can Renovate Your Portfolio
- Vera Bradley Stock Getting Cheap
- 3 Education Stocks to Enroll in This Summer
- 免費獲取StockNews.com關於ProShares UltraShort納斯達克生物技術的研究報告
- 在這三個升級中保持防禦
- 想拋售這3只可能退市的中國股票嗎?讓我們來看看。
- 3只家裝類股,可以重塑你的投資組合
- 維拉·布拉德利的股票越來越便宜
- 3只教育類股將於今夏入圍
Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
獲得ProShares UltraShort納斯達克生物科技日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProShares UltraShort納斯達克生物技術和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。